DTP(디프테리아, 파상풍, 백일해) 백신 시장 : 시장 규모, 점유율 , 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is witnessing robust growth due to the rising burden of vaccine-preventable bacterial diseases and increasing global immunization initiatives. According to Fortune Business Insights, the global DTP vaccines market was valued at USD 11.69 billion in 2025. The market is projected to grow from USD 13.44 billion in 2026 to USD 46.46 billion by 2034, registering a strong CAGR of 16.77% during the forecast period. In 2025, North America dominated the global market with a share of 40.92%, supported by high vaccination coverage and a strong healthcare infrastructure.

DTP vaccines are combination vaccines that protect against three serious bacterial infections-diphtheria, tetanus, and pertussis. These vaccines are widely administered to infants, children, adolescents, adults, and pregnant women in various forms such as DTaP, Tdap, and DT/Td vaccines. The severe complications associated with these diseases, including pneumonia, seizures, airway obstruction, and muscle spasms, have significantly increased the demand for preventive vaccination globally.

Market Dynamics

Market Drivers

The rising prevalence of bacterial respiratory infections is a major factor driving market growth. Pertussis, caused by Bordetella pertussis, is highly contagious and poses a significant risk to infants and young children. The increasing number of reported pertussis cases globally has shifted focus toward timely vaccination and booster doses. Growing emphasis on pediatric immunization schedules and active government participation in vaccination programs are further supporting market expansion.

Market Restraints

Despite strong growth drivers, the market faces challenges due to vaccine hesitancy and lack of awareness regarding immunization schedules, particularly in low-income and developing regions. Religious beliefs, misinformation regarding vaccine safety, and inadequate healthcare infrastructure contribute to missed doses and incomplete immunization, restricting market growth and increasing the risk of disease outbreaks.

Market Opportunities

Government-led vaccination initiatives present significant growth opportunities for the market. Several countries are strengthening national immunization programs to improve vaccine coverage among infants, children, and adults. Global alliances and organizations are also introducing booster programs and combination vaccines to reduce disease burden and healthcare costs. These initiatives are expected to enhance vaccine adoption and support market growth through 2034.

Market Challenges

Limited cold chain infrastructure remains a major challenge, particularly in resource-limited regions. DTP vaccines require strict temperature control throughout storage and transportation. Inadequate refrigeration facilities and unreliable logistics often lead to vaccine wastage, reduced potency, and increased operational costs, thereby restraining market growth.

DTP Vaccines Market Trends

Technological advancements in vaccine development are shaping the future of the DTP vaccines market. Traditional chemically inactivated vaccines are associated with reduced immunogenicity and the need for multiple booster doses. As a result, manufacturers are increasingly shifting toward recombinant vaccine technologies that offer improved safety, stronger immune responses, and longer-lasting protection. These innovations are expected to significantly influence market growth during the forecast period.

Segmentation Analysis

By technology, the inactivated vaccines segment dominated the market, driven by the wide availability of approved products and high global vaccination coverage. However, recombinant and other advanced technologies are expected to grow at a notable rate due to increasing research and development activities.

By type, the DTaP vaccine segment held the largest market share, supported by its widespread use in pediatric immunization programs. The Tdap segment accounted for a substantial share due to its role as a booster vaccine for adolescents, adults, and pregnant women.

By age group, the pediatric segment dominated the market, owing to strong recommendations for early-life immunization and higher disease risk among children. The adult segment also contributed significantly due to routine booster doses and maternal immunization programs.

By distribution channel, government suppliers accounted for the largest share, driven by national immunization programs and bulk procurement of vaccines. Hospital and retail pharmacies are expected to grow steadily due to improved access and convenience.

Regional Outlook

North America dominated the market in 2025, supported by high disease awareness, strong immunization coverage, and the presence of key market players.

Asia Pacific held the second-largest share and is expected to grow at the highest CAGR due to increasing disease prevalence, government vaccination campaigns, and affordable vaccine availability.

Europe maintained a substantial market share, driven by advanced healthcare systems and structured immunization programs.

Latin America and the Middle East & Africa are expected to grow steadily due to rising vaccination initiatives and increasing efforts to eliminate vaccine-preventable diseases.

Competitive Landscape

The market is consolidated, with major players such as GSK plc, Sanofi, and Merck & Co., Inc. holding a significant share. Other notable players include Serum Institute of India, BioNet-Asia, and Wuhan Institute of Biological Products. These companies are focusing on product innovation, strategic collaborations, and regulatory approvals to strengthen their global presence.

Conclusion

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is set for substantial growth over the forecast period, supported by rising bacterial disease prevalence, expanding immunization programs, and continuous advancements in vaccine technologies. With the market valued at USD 11.69 billion in 2025, projected to reach USD 13.44 billion in 2026 and USD 46.46 billion by 2034, increasing government initiatives, pediatric immunization focus, and recombinant vaccine development are expected to sustain long-term market expansion despite challenges related to vaccine awareness and cold chain limitations.

Segmentation By Technology

• Inactivated
• Others

By Type

• DTaP Vaccine
• Tdap Vaccine
• DT/ Td vaccines
• Others

By Age Group

• Pediatric
• Adults

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Technology, Type, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries, 2025
• 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries

5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Inactivated
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. DTaP Vaccine
  • 5.2.2. Tdap Vaccine
  • 5.2.3. DT/ Td vaccines
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adolts
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Inactivated
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. DTaP Vaccine
  • 6.2.2. Tdap Vaccine
  • 6.2.3. DT/ Td vaccines
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adolts
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Inactivated
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. DTaP Vaccine
  • 7.2.2. Tdap Vaccine
  • 7.2.3. DT/ Td vaccines
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adolts
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Inactivated
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. DTaP Vaccine
  • 8.2.2. Tdap Vaccine
  • 8.2.3. DT/ Td vaccines
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adolts
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Inactivated
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. DTaP Vaccine
  • 9.2.2. Tdap Vaccine
  • 9.2.3. DT/ Td vaccines
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adolts
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Inactivated
  • 10.1.2. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. DTaP Vaccine
  • 10.2.2. Tdap Vaccine
  • 10.2.3. DT/ Td vaccines
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adolts
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Boryung Biopharma Co.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Serum Institute of India Pvt. Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. BioNet-Asia.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bio Farma
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Biological E Limited.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)